Topiramate
Code | Size | Price |
---|
TAR-T0675-25mg | 25mg | £101.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0675-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0675-50mg | 50mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0675-100mg | 100mg | £123.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T0675-200mg | 200mg | £160.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Topiramate is a unique antiseizure medication that is used in the treatment of partial and generalized seizures. Topiramate has been rarely associated with hepatic injury and largely when used in combination with other anticonvulsant medications.
CAS:
97240-79-4
Formula:
C12H21NO8S
Molecular Weight:
339.36
Pathway:
Neuroscience; Metabolism; Membrane transporter/Ion channel
Purity:
0.98
SMILES:
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1
Target:
Potassium Channel; Calcium Channel; GABA Receptor; Sodium Channel; GluR; Carbonic Anhydrase; iGluR
References
1. Taverna S, et al. J Pharmacol Exp Ther, 1999, 288(3), 960-968.
2. Gryder DS, et al. J Neurosci, 2003, 23(18), 7069-7074.
3. Yang Y, et al. Brain Res, 1998, 804(2), 169-176.
4. Kaminski RM, et al. Neuropharmacology, 2004, 46(8), 1097-1104.
5. Koh S, et al. Ann Neurol, 2001, 50(3), 366-372.